AstraZeneca

FALCON | D699BC00001

NCT01602380

McG1227

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

ER+, PR+

Investigational

Product

Faslodex

Treatment Arms

o Experimental: faslodex+placebo

o Active Comparator: arimidex +placeb